UCB

UCB is a multinational biopharmaceutical company specializing in neurological and immunological diseases. The company was founded in 1928 and focuses on developing therapies for epilepsy, Parkinson's disease, Crohn's disease, and rheumatoid arthritis, among other conditions. UCB has a varied portfolio of drugs, including Keppra for epilepsy and Cimzia for rheumatoid arthritis and Crohn's disease.